Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
· regeneron pharmaceuticals, inc.
AI Briefing
- Dupixent approved in Japan for bullous pemphigoid
- Dupixent shows significant efficacy in moderate-to-severe BP patients
- Dupixent experiences improved disease remission in pivotal trial
Advertisement